Canadian Cancer Trials Group Bulletins


Recent Publication

CCTG LY.12 - A Phase III Study of Gemcitabine, Dexamethasone, and Cisplatin Compared to Dexamethasone, Cytarabine, and Cisplatin Plus/Minus Rituximab [(R)-GDP VS (R)-DHAP] as Salvage Chemotherapy for Patients with Relapsed or Refractory Aggressive Histology Non-Hodgkin's Lymphoma Prior to Autologous Stem Cell Transplant and Followed by Maintenance Rituximab Versus Observation

This most recent publication reports results of a sub-group analysis from CCTG LY.12.

Davison K, Chen BE, Kukreti V, Couban S, Benger A, Berinstein N, Kaizer L, Desjardins P, Mangel J, Zhu L, Djurfeldt MS, Hay AE, Shepherd L, Crump M. Treatment outcomes for older patients with relapsed/refractory aggressive lymphoma receiving salvage chemotherapy and autologous stem cell transplantation are similar to younger patients: a subgroup analysis from the Phase III CCTG LY.12 Trial. Ann Oncol. 2016 Dec 19. pii: mdw653. [Epub ahead of print].